Win a Grant to the C3 in Orlando, Florida

Participe por una beca para asistir al C3 en Orlando, FloridaFrom June 27th to June 30th, Orlando, Florida will hold the Complex Cardiovascular Catheter Therapeutics (C3 Conference), an event with a steadily growing number of attendees each year.

 

The Conference Organizing Committee grants, through SOLACI, five scholarships for professionals aiming to present their approved work or complex case.

 

Scholarships include the following:

  • Congress registration fee.
  • Three nights lodging for the aforementioned date.
  • Plane tickets through the Congress official travel agency (with a maximum limit of USD 1000).

 

 

How can you submit your work? 

Cases shall be submitted through the following form:

Enter 
(Spanish form)

 

Your presentation must fulfill the following requirements:

    • Submit a “.doc” or “.docx” file with the description of the case to be presented. The text must be up to 300 words long, in an 11 pt font.

 

    • Submit a supplementary “.ppt” or “.pptx” file with the case presentation. While videos (up to 5) will be admitted for use during the oral presentation, this initial file can only include up to 5 fixed images.

 

    • Case and description must be submitted in english.
  •  
    • Presenters can submit more than one case. In such a circumstance, they shall make different submissions, one for each presentation.
 

Submission deadline: March 30th, 2018.

 

C3 is a Congress designed for physicians who specialize in interventional cardiology, vascular surgery, and interventional radiology, as well as fellows, residents, and other healthcare professionals interested in atherosclerotic cardiovascular disease. C3 offers presentations and debates with expert global faculty, live and pre-recorded cases, industry-sponsored and supported symposia, exhibit booths and simulators, poster sessions, case presentations and hands-on workshops.

 

Learn more www.c3conference.net


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

 

More articles by this author

ACC 2026: SURViV Trial Results – Exclusive Presentation and Analysis with Dr. Dimytri Siqueira

Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

SOLACI Technicians Webinar – Ultrasound Pulses + Calcium = Coronary Lithotripsy

The Latin American Society of Interventional Cardiology (SOLACI) invites you to participate in a new Live SOLACI Webinar specially designed for technicians, nurses, and...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...